Olverembatinib: resistant CML and the T315I mutation: consultation records checklist

1. Bring all bone marrow, blood count and CML phase reports to assess the next treatment pathway
2. Organise BCR::ABL1 quantitative trends and kinase domain mutation reports to identify the resistance issue
3. List each TKI's dose, start and stop dates and reason for stopping to distinguish resistance from intolerance
4. Provide cardiovascular and cerebrovascular history, recent biochemistry and a full medication list to plan safety monitoring

Questions to clarify
- Do I meet the eligibility criteria?
- What are the separate medical and coordination service costs without Chinese health insurance or free-drug assistance?
- How are initial treatment, ongoing treatment, return travel and follow-up arranged?
- Which risks require immediate contact with the hospital?

An initial service consultation does not replace medical assessment.